|Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years|
DC Klonoff, JB Buse, LL Nielsen, X Guan, CL Bowlus, JH Holcombe, ...
Current medical research and opinion 24 (1), 275-286, 2008
|Continuous glucose monitoring: roadmap for 21st century diabetes therapy|
Diabetes care 28 (5), 1231-1239, 2005
|Threshold-based insulin-pump interruption for reduction of hypoglycemia|
RM Bergenstal, DC Klonoff, SK Garg, BW Bode, M Meredith, RH Slover, ...
New England Journal of Medicine 369 (3), 224-232, 2013
|An economic analysis of interventions for diabetes.|
DC Klonoff, DM Schwartz
Diabetes care 23 (3), 390-404, 2000
|Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open …|
JB Buse, DC Klonoff, LL Nielsen, X Guan, CL Bowlus, JH Holcombe, ...
Clinical therapeutics 29 (1), 139-153, 2007
|Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP)|
RM Bergenstal, AJ Ahmann, T Bailey, RW Beck, J Bissen, B Buckingham, ...
Diabetes technology & therapeutics 15 (3), 198-211, 2013
|Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States|
B Bode, V Garrett, J Messler, R McFarland, J Crowe, R Booth, DC Klonoff
Journal of diabetes science and technology 14 (4), 813-821, 2020
|Noninvasive blood glucose monitoring|
Diabetes care 20 (3), 433-437, 1997
|Continuous glucose monitoring: an endocrine society clinical practice guideline|
DC Klonoff, B Buckingham, JS Christiansen, VM Montori, WV Tamborlane, ...
The Journal of Clinical Endocrinology & Metabolism 96 (10), 2968-2979, 2011
|Reagent-less whole-blood glucose meter|
BB Sterling, PC Hartstein, KI Li, MD Agostino, DC Klonoff, RD Gaffney, ...
US Patent 6,958,809, 2005
|Method and apparatus for improving the accuracy of alternative site analyte concentration measurements|
P Rule, J Braig, P Hartstein, H Smith, D Klonoff
US Patent App. 10/302,071, 2003
|Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach|
MJ Demeure, DC Klonoff, JH Karam, QY Duh, OH Clark
Surgery 110 (6), 998-1005, 1991
|Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study|
S Garg, RL Brazg, TS Bailey, BA Buckingham, RH Slover, DC Klonoff, ...
Diabetes technology & therapeutics 14 (3), 205-209, 2012
|The current status of mHealth for diabetes: will it be the next big thing?|
Journal of diabetes science and technology 7 (3), 749-758, 2013
|Continuous glucose monitoring: a review of the technology and clinical use|
DC Klonoff, D Ahn, A Drincic
Diabetes Research and Clinical Practice 133, 178-192, 2017
|A review of continuous glucose monitoring technology|
Diabetes Technology & Therapeutics 7 (5), 770-775, 2005
|Consensus report: the current role of self-monitoring of blood glucose in non-insulin-treated type 2 diabetes|
DC Klonoff, L Blonde, G Cembrowski, AR Chacra, G Charpentier, ...
Journal of diabetes science and technology 5 (6), 1529-1548, 2011
|Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19|
SA Meo, DC Klonoff, J Akram
Eur Rev Med Pharmacol Sci 24 (8), 4539-4547, 2020
|Diabetes technology update: use of insulin pumps and continuous glucose monitoring in the hospital|
GE Umpierrez, DC Klonoff
Diabetes care 41 (8), 1579-1589, 2018
|Macroamylasemia and other immunoglobulin-complexed enzyme disorders|
Western Journal of Medicine 133 (5), 392, 1980